Difference between revisions of "Tacrolimus (Prograf)"
m |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as [[GVHD|graft versus host disease]], allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.<ref name="insert">[http://www.astellas.us/docs/prograf.pdf Tacrolimus (Prograf) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/tacrolimus.pdf Tacrolimus (Prograf) package insert (locally hosted backup)]</ref><ref>[http://prograf.com/ Prograf manufacturer's website]</ref> | Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as [[GVHD|graft versus host disease]], allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.<ref name="insert">[http://www.astellas.us/docs/prograf.pdf Tacrolimus (Prograf) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/tacrolimus.pdf Tacrolimus (Prograf) package insert (locally hosted backup)]</ref><ref>[http://prograf.com/ Prograf manufacturer's website]</ref> | ||
| Line 11: | Line 9: | ||
*[http://www.astellas.us/docs/prograf.pdf#page=38 Tacrolimus (Prograf) package insert PDF pages 38-42]<ref name="insert"></ref> | *[http://www.astellas.us/docs/prograf.pdf#page=38 Tacrolimus (Prograf) package insert PDF pages 38-42]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/tacrolimus-systemic-patient-drug-information Tacrolimus (Prograf) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tacrolimus-systemic-patient-drug-information Tacrolimus (Prograf) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/tacrolimus-systemic-patient-drug-information Tacrolimus (Prograf) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tacrolimus-systemic-patient-drug-information Tacrolimus (Prograf) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' FK-506 | ||
| + | *'''Brand names:''' Advagraf, Prograf | ||
==References== | ==References== | ||
| Line 16: | Line 18: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Calcineurin inhibitors]] | [[Category:Calcineurin inhibitors]] | ||
Revision as of 02:13, 30 September 2017
General information
Class/mechanism: Immunosuppresive medication, calcineurin-inhibitor, inhibits T-cell activity. Exact mechanism of action unknown, but it may involve tacrolimus binding to the intracellular protein FKBP-12, which results in the formation of a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This complex inhibits calcineurin's phosphatase activity and may prevent NF-AT (nuclear factor of activated T-cells) activity, which is believed to be responsible for transcription of lymphokines such as interleukin-2 and gamma interferon). Tacrolimus's activity may involve inhibiting humoral immunity and cell-mediated reactions such as graft versus host disease, allograft rejection, collagen-induced arthritis, delayed type hypersensitivity, and experimental allergic encephalomyelitis.[1][2][3]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Tacrolimus (Prograf) package insert PDF pages 38-42[1]
- Tacrolimus (Prograf) patient drug information (UpToDate)[4]
Also known as
- Code name: FK-506
- Brand names: Advagraf, Prograf